A systematic review and meta-analysis of the association between the D-dimer and rheumatic diseases.
autoimmunity
disease activity
d‐dimer
hypercoagulability
inflammation
rheumatic diseases
venous thromboembolism
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
30
05
2024
received:
30
03
2024
accepted:
06
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
26
7
2024
Statut:
ppublish
Résumé
There is good evidence that specific autoimmune rheumatic diseases (RDs), for example, rheumatoid arthritis and systemic lupus erythematosus (SLE), are associated with a state of hypercoagulability and an increased risk of venous thromboembolism (VTE). However, limited information regarding this association is available for other autoimmune or autoinflammatory RDs. We sought to address this issue by conducting a systematic review and meta-analysis of the association between the d-dimer, an established marker of hypercoagulability and VTE, and RDs and the possible clinical and demographic factors mediating this association. We searched the electronic databases PubMed, Web of Science, and Scopus from inception to January 31, 2024. The risk of bias and the certainty of evidence were assessed using the Joanna Briggs Institute Critical Appraisal Checklist and GRADE, respectively. In 31 studies selected for analysis (2724 RD patients and 3437 healthy controls), RD patients had overall significantly higher d-dimer concentrations when compared to controls (standard mean difference = 0.93, 95% CI 0.76-1.10, p < .001; I Overall, patients with RDs have significantly higher d-dimer concentrations when compared with healthy controls, indicating a state of hypercoagulability. The alterations in d-dimer concentrations are mediated by age, specific RD and RD category, RD duration, and markers of anticoagulation and inflammation. Further research is warranted to investigate d-dimer concentrations across the spectrum of RDs and their utility in predicting and managing VTE in these patients (PROSPERO registration number: CRD42024517712).
Substances chimiques
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
Biomarkers
0
Types de publication
Systematic Review
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1349Informations de copyright
© 2024 The Author(s). Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Calle E, Gómez‐Puerta JA. The spectrum of rheumatic diseases. Surgery in rheumatic and musculoskeletal disease. Handbook Systemic Autoimmune Dis. 2018;15:1‐13.
McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. doi:10.1371/journal.pmed.0030297
Moutsopoulos HM. Autoimmune rheumatic diseases: one or many diseases. J Translational Autoimmunity. 2021;4:100129. doi:10.1016/j.jtauto.2021.100129
Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(3):351‐360. doi:10.1016/j.semarthrit.2017.05.010
Korotaeva T, Dina O, Holdsworth E, et al. Investigating diagnosis, treatment, and burden of disease in patients with ankylosing spondylitis in Central Eastern Europe and the United States: a real‐world study. Clin Rheumatol. 2021;40(12):4915‐4926. doi:10.1007/s10067-021-05864-8
Chen Y, Wu L, Hernández‐Muñoz J, et al. The economic burden of systemic sclerosis—a systematic review. Int J Rheumatic Diseases. 2022;25(2):110‐120. doi:10.1111/1756-185X.14270
Safiri S, Kolahi AA, Smith E, et al. Global, regional and national burden of osteoarthritis 1990‐2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79(6):819‐828. doi:10.1136/annrheumdis-2019-216515
Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605‐620. doi:10.1038/nrrheum.2016.137
Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990‐2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463‐1471. doi:10.1136/annrheumdis-2019-215920
Ben Mrid R, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L. Anti‐rheumatoid drugs advancements: new insights into the molecular treatment of rheumatoid arthritis. Biomed Pharmacother. 2022;151:113126. doi:10.1016/j.biopha.2022.113126
Jung SM, Kim WU. Targeted immunotherapy for autoimmune disease. Immune Netw. 2022;22(1):e9. doi:10.4110/in.2022.22.e9
Reynolds JA, Putterman C. Progress and unmet needs in understanding fundamental mechanisms of autoimmunity. J Autoimmun. 2023;137:102999. doi:10.1016/j.jaut.2023.102999
Fugger L, Jensen LT, Rossjohn J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. Cell. 2020;181(1):63‐80. doi:10.1016/j.cell.2020.03.007
Havnaer A, Han G. Autoinflammatory disorders: a review and update on pathogenesis and treatment. Am J Clin Dermatol. 2019;20(4):539‐564. doi:10.1007/s40257-019-00440-y
Efthimiou P, Petryna O, Nakasato P, Kontzias A. New insights on multigenic autoinflammatory diseases. Ther Adv Musculoskelet Dis. 2022;14:1759720X221117880. doi:10.1177/1759720X221117880
Kawakami A, Endo Y, Koga T, Yoshiura K, Migita K. Autoinflammatory disease: clinical perspectives and therapeutic strategies. Inflamm Regen. 2022;42(1):37. doi:10.1186/s41232-022-00217-7
Misra DP, Ahmed S, Goyal M, Sharma A, Agarwal V. Venous thromboembolism in the inflammatory rheumatic diseases. Rheumatic Dis Clin North Am. 2023;49(1):97‐127. doi:10.1016/j.rdc.2022.08.001
Menichelli D, Cormaci VM, Marucci S, et al. Risk of venous thromboembolism in autoimmune diseases: a comprehensive review. Autoimmun Rev. 2023;22(11):103447. doi:10.1016/j.autrev.2023.103447
Ketfi C, Boutigny A, Mohamedi N, et al. Risk of venous thromboembolism in rheumatoid arthritis. Joint Bone Spine. 2021;88(3):105122. doi:10.1016/j.jbspin.2020.105122
Wang F, Liu J, Fang Y, et al. Hypercoagulability in rheumatoid arthritis: a bibliometric analysis and retrospective data mining study. ACS Omega. 2023;8(50):48522‐48534. doi:10.1021/acsomega.3c08460
Omair MA, Alkhelb SA, Ezzat SE, Boudal AM, Bedaiwi MK, Almaghlouth I. Venous thromboembolism in rheumatoid arthritis: the added effect of disease activity to traditional risk factors. Open Access Rheumatol: Res Rev. 2022;14:231‐242. doi:10.2147/OARRR.S284757
Chung WS, Lin CL, Chang SN, Lu CC, Kao CH. Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. J Thromb Haemostasis. 2014;12(4):452‐458. doi:10.1111/jth.12518
Bello N, Meyers KJ, Workman J, Marcano Belisario J, Cervera R. Systematic literature review and meta‐analysis of venous thromboembolism events in systemic lupus erythematosus. Rheumatol Ther. 2023;10(1):7‐34. doi:10.1007/s40744-022-00513-1
Ungprasert P, Srivali N, Kittanamongkolchai W. Systemic sclerosis and risk of venous thromboembolism: a systematic review and meta‐analysis. Modern Rheumatol. 2015;25(6):893‐897. doi:10.3109/14397595.2015.1038456
Liapi M, Jayne D, Merkel PA, Segelmark M, Mohammad AJ. Venous thromboembolism in ANCA‐associated vasculitis: a population‐based cohort study. Rheumatology. 2021;60(10):4616‐4623. doi:10.1093/rheumatology/keab057
Isaacs B, Gapud EJ, Antiochos B, Seo P, Geetha D. Venous thrombotic events in ANCA‐associated vasculitis: incidence and risk factors. Kidney360. 2020;1(4):258‐262. doi:10.34067/KID.0000572019
Hansrivijit P, Trongtorsak A, Gadhiya KP, et al. Incidence and risk factors of venous thromboembolism in ANCA‐associated vasculitis: a meta‐analysis and metaregression. Clin Rheumatol. 2021;40(7):2843‐2853. doi:10.1007/s10067-021-05589-8
Stassen PM, Derks RPH, Kallenberg CGM, Stegeman CA. Venous thromboembolism in ANCA‐associated vasculitis: incidence and risk factors. Rheumatology. 2007;47(4):530‐534. doi:10.1093/rheumatology/ken035
Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA‐associated vasculitis: a 20‐year population‐based cohort study. Mayo Clin Proc. 2018;93(5):597‐606. doi:10.1016/j.mayocp.2018.02.010
Kang A, Antonelou M, Wong NL, et al. High incidence of arterial and venous thrombosis in antineutrophil cytoplasmic antibody‐associated vasculitis. J Rheumatol. 2019;46(3):285‐293. doi:10.3899/jrheum.170896
Kronbichler A, Leierer J, Leierer G, et al. Clinical associations with venous thromboembolism in anti‐neutrophil cytoplasm antibody‐associated vasculitides. Rheumatology. 2017;56(5):kew465. doi:10.1093/rheumatology/kew465
Guo Y, Zhou F, Xu H. Gout and risk of venous thromboembolism: a systematic review and meta‐analysis of cohort studies. Int J Rheumatic Dis. 2023;26(2):344‐353. doi:10.1111/1756-185X.14524
Zeng C, Bennell K, Yang Z, et al. Risk of venous thromboembolism in knee, hip and hand osteoarthritis: a general population‐based cohort study. Ann Rheum Dis. 2020;79(12):1616‐1624. doi:10.1136/annrheumdis-2020-217782
Lee NH, Bae M, Jin M, Chung SW, Lee CW, Jeon CH. Characterization of venous involvement in Vasculo‐Behçet disease. Korean J Thorac Cardiovasc Surg. 2020;53(6):381‐386. doi:10.5090/kjtcs.20.027
Alibaz‐Oner F, Aldag B, Aldag M, et al. Post‐thrombotic syndrome and venous disease‐specific quality of life in patients with vascular Behçet's disease. J Vascular Surg: Venous Lymphatic Disorders. 2016;4(3):301‐306. doi:10.1016/j.jvsv.2016.01.003
Toledo‐Samaniego N, Oblitas CM, Peñaloza‐Martínez E, et al. Arterial and venous involvement in Behçet's syndrome: a narrative review. J Thromb Thrombolysis. 2022;54(1):162‐171. doi:10.1007/s11239-022-02637-1
Houman MH, Ben Ghorbel I, Khiari Ben Salah I, Lamloum M, Ben Ahmed M, Miled M. Deep vein thrombosis in Behcet's disease. Clin Exp Rheumatol. 2001;19(5 suppl 24):S48‐S50.
Keser G. Inflammation‐induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012;18(11):1478‐1493. doi:10.2174/138161212799504731
Peshkova AD, Evdokimova TA, Sibgatullin TB, Ataullakhanov FI, Litvinov RI, Weisel JW. Accelerated spatial fibrin growth and impaired contraction of blood clots in patients with rheumatoid arthritis. Int J Mol Sci. 2020;21(24):9434. doi:10.3390/ijms21249434
Tamaki H, Khasnis A. Venous thromboembolism in systemic autoimmune diseases: a narrative review with emphasis on primary systemic vasculitides. Vasc Med. 2015;20(4):369‐376. doi:10.1177/1358863X15573838
Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80(2):169‐175. doi:10.1136/annrheumdis-2020-218419
Yoshimura M, Fujieda Y, Sugawara M, et al. Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time‐averaged DAS28CRP: a nested case‐control study. Rheumatol Int. 2022;42(11):1939‐1946. doi:10.1007/s00296-022-05121-4
Ferreira KS, Cicarini WB, Alves LCV, et al. Correlation between active disease and hypercoagulability state in patients with systemic lupus erythematosus. Clin Chim Acta. 2019;490:107‐112. doi:10.1016/j.cca.2018.12.008
Olson JD. D‐dimer: an overview of hemostasis and fibrinolysis, assays, and clinical applications. Adv Clin Chem. 2015;69:1‐46. doi:10.1016/bs.acc.2014.12.001
Johnson ED, Schell JC, Rodgers GM. The D‐dimer assay. Am J Hematol. 2019;94(7):833‐839. doi:10.1002/ajh.25482
Favresse J, Lippi G, Roy PM, et al. D‐dimer: preanalytical, analytical, postanalytical variables, and clinical applications. Crit Rev Clin Lab Sci. 2018;55(8):548‐577. doi:10.1080/10408363.2018.1529734
Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D‐dimer. J Am Coll Cardiol. 2017;70(19):2411‐2420. doi:10.1016/j.jacc.2017.09.024
Wauthier L, Favresse J, Hardy M, et al. D‐dimer testing: a narrative review. Adv Clin Chem. 2023;114:151‐223. doi:10.1016/bs.acc.2023.02.006
Bloom BJ, Tucker LB, Miller LC, Schaller JG. Fibrin D‐dimer as a marker of disease activity in systemic onset juvenile rheumatoid arthritis. J Rheumatol. 1998;25(8):1620‐1625.
Mukubo Y, Kawamata M. Higher preoperative D‐dimer value remain high postoperatively in patients with rheumatoid arthritis compared with those with osteoarthrosis. J Anesth. 2006;20(1):51‐53. doi:10.1007/s00540-005-0368-3
Mori S, Soejima H, Hokamaki J, Tsujita K. Clinical disease activity is a major determinant of plasma D‐dimer elevation in outpatients with rheumatoid arthritis: a hospital‐based cross‐sectional study. Modern Rheumatol. 2024;34(2):313‐321. doi:10.1093/mr/road018
Moola S, Munn Z, Tufanaru C, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, eds. Joanna Briggs Institute Reviewer's Manual. Johanna Briggs Institute; 2017.
Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. J Clin Epidemiol. 2011;64(4):401‐406. doi:10.1016/j.jclinepi.2010.07.015
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. doi:10.1186/1471-2288-14-135
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Stat Med. 2002;21(11):1539‐1558. doi:10.1002/sim.1186
Higgins JPT. Measuring inconsistency in meta‐analyses. BMJ. 2003;327(7414):557‐560. doi:10.1136/bmj.327.7414.557
Tobias A. Assessing the influence of a single study in the meta‐analysis estimate. Stata Technical Bulletin. 1999;47:15‐17.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088‐1101.
Sterne JAC, Egger M. Funnel plots for detecting bias in meta‐analysis. J Clin Epidemiol. 2001;54(10):1046‐1055. doi:10.1016/s0895-4356(01)00377-8
Duval S, Tweedie R. Trim and fill: a simple funnel‐plot‐based method of testing and adjusting for publication bias in meta‐analysis. Biometrics. 2000;56(2):455‐463. doi:10.1111/j.0006-341x.2000.00455.x
Orem A, Deger O, Memis O, Bahadir S, Ovali E, Cimsit G. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behcet's disease. Ann Rheum Dis. 1995;54(9):726‐729. doi:10.1136/ard.54.9.726
Akazawa H, Ikeda U, Yamamoto K, Kuroda T, Shimada K. Hypercoagulable state in patients with Takayasu's arteritis. Thromb Haemostasis. 1996;75(5):712‐716.
Ames PR, Lupoli S, Alves J, et al. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. Rheumatology. 1997;36(10):1045‐1050. doi:10.1093/rheumatology/36.10.1045
Cheras PA, Whitaker AN, Blackwell EA, Sinton TJ, Chapman MD, Peacock KA. Hypercoagulability and hypofibrinolysis in primary osteoarthritis. Clin Orthop Relat Res. 1997;334:57‐67.
Ichikawa Y, Yamada C, Horiki T, Hoshina Y, Uchiyama M. Serum matrix metalloproteinase‐3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin Exp Rheumatol. 1998;16(5):533‐540.
Kamper EF, Kopeikina LT, Trontzas P, Potamianou A, Tsiroglou E, Stavridis JC. The effect of disease activity related cytokines on the fibrinolytic potential and cICAM‐1 expression in rheumatoid arthritis. J Rheumatol. 2000;27(11):2545‐2550.
McEntegart A. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology. 2001;40(6):640‐644. doi:10.1093/rheumatology/40.6.640
Wållberg‐Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapää‐Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol. 2002;29(5):875‐882.
So AK, Varisco PA, Kemkes‐Matthes B, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemostasis. 2003;1(12):2510‐2515. doi:10.1111/j.1538-7836.2003.00462.x
Bunescu A, Seideman P, Lenkei R, Levin K, Egberg N. Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol. 2004;31(12):2347‐2355.
Afeltra A, Vadacca M, Conti L, et al. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. Arthritis Rheumatism. 2005;53(3):452‐459. doi:10.1002/art.21172
Ingegnoli F, Fantini F, Favalli EG, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor‐α blockade. J Autoimmun. 2008;31(2):175‐179. doi:10.1016/j.jaut.2008.07.002
Marie I, Borg JY, Hellot MF, Levesque H. Plasma D‐dimer concentration in patients with systemic sclerosis. Br J Dermatol. 2007;158(2):392‐395. doi:10.1111/j.1365-2133.2007.08313.x
Suzuki E, Amengual O, Atsumi T, et al. Increased expression of phospholipid scramblase 1 in monocytes from patients with systemic lupus erythematosus. J Rheumatol. 2010;37(8):1639‐1645. doi:10.3899/jrheum.091420
Fernández‐Bello I, López‐Longo FJ, Arias‐Salgado EG, Jiménez‐Yuste V, Butta NV. Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity. Orphanet J Rare Dis. 2013;8:81. doi:10.1186/1750-1172-8-81
Mejia JC, Espinosa G, Tassies D, Reverter JC, Cervera R. Endogenous thrombin potential in Behcet's disease: relationship with thrombosis and anticoagulant therapy. Clin Exp Rheumatol. 2014;32(4 suppl 84):S67‐S71.
Salmela A, Ekstrand A, Joutsi‐Korhonen L, Räisänen‐Sokolowski A, Lassila R. Activation of endothelium, coagulation and fibrinolysis is enhanced and associates with renal anti‐neutrophil cytoplasmic antibody‐associated vasculitis. Nephrol Dial Transplant. 2015;30(suppl 1):i53‐9. doi:10.1093/ndt/gfu379
Ma J, Zhang Y, Gong Y, Zhu Y, Li M, Zhao J. Correlation between plasma levels of D‐dimer and IL‐1, IL‐6, and TNF‐α in patients with rheumatoid arthritis. Int J Clin Exp Med. 2018;11(9):9865‐9871.
Chen S, Huang X, Huang Y, et al. Role of plasma fibrinogen in assessing disease activity of patients with gout. Clin Chim Acta. 2020;510:483‐487. doi:10.1016/j.cca.2020.08.012
Cicarini WB, Duarte RCF, Ferreira KS, et al. Impact of markers of endothelial injury and hypercoagulability on systemic lupus erythematosus. Lupus. 2020;29(2):182‐190. doi:10.1177/0961203319899478
Oh YJ, Park EH, Park JW, Song YW, Lee EB. Practical utility of D‐dimer test for venous thromboembolism in systemic lupus erythematosus depends on disease activity: a retrospective cohort study. J Korean Med Sci. 2020;35(43):e356. doi:10.3346/jkms.2020.35.e356
Tan L, Hua L, Zhao Y, et al. Clinical study of serum markers and immune protein expression in patients with ANCA‐associated vasculitis. Acta Med Mediterr. 2020;36:1239‐1244. doi:10.19193/0393-6384_2020_2_194
Wu KL, Liang QH, Ding N, Li BW, Hao J. Sphingosine‐1‐phosphate in anti‐neutrophil cytoplasmic antibody‐associated vasculitis: coagulation‐related clinical indicators and complications. Biosci Rep. 2020;40(10):BSR20200157. doi:10.1042/BSR20200157
Feng J, Li J, Li Y, Jin Y, Du F, Chen X. Elevated serum D‐dimer may reflect the presence of gut inflammation in spondyloarthritis. Front Med. 2022;8:8. doi:10.3389/fmed.2021.816422
Huang Y, Chen L, Zhu B, Han H, Hou Y, Wang W. Evaluation of systemic lupus erythematosus disease activity using anti‐α‐enolase antibody and RDW. Clin Exp Med. 2021;21(1):73‐78. doi:10.1007/s10238-020-00657-w
Roldan LP, Roldan PC, Sibbitt Jr. WL, Qualls CR, Ratliff MD, Roldan CA. Aortic adventitial thickness as a marker of aortic atherosclerosis, vascular stiffness, and vessel remodeling in systemic lupus erythematosus. Clin Rheumatol. 2021;40(5):1843‐1852. doi:10.1007/s10067-020-05431-7
Xue L, Tao L, Li X, et al. Plasma fibrinogen, D‐dimer, and fibrin degradation product as biomarkers of rheumatoid arthritis. Sci Rep. 2021;11(1):16903. doi:10.1038/s41598-021-96349-w
Zheng CS, Qin XJ, Ni H, Chen RY, Liu JL, Wang WH. Evaluation of disease activity of systemic lupus erythematosus by D‐dimer combined with red blood cell distribution width. Clin Lab. 2021;67(9). doi:10.7754/Clin.Lab.2021.210118
Göğebakan H, Cerrah S. The role of plasma fibrinogen, D‐dimer and fibrinogen degradation products in diagnosis and disease activity in patients with ankylosing spondylitis. Egyptian Rheumatol. 2022;44(1):47‐51. doi:10.1016/j.ejr.2021.08.002
Qiang F, Xu H, Sheng J. Relationship between plasma fibrinogen degradation products(FDP) and D‐dimer levels and disease activity in rheumatoid arthritis: a STROBE compliant article. Medicine. 2022;101(36):e30455. doi:10.1097/MD.0000000000030455
Wang Q, Dai SM. An interaction between the inflammatory condition and the hypercoagulable condition occurs in primary Sjögren syndrome. Clin Rheumatol. 2023;42(4):1107‐1112. doi:10.1007/s10067-022-06498-0
Cohen J. Statistical power analysis. Current Directions Psychol Sci. 1992;1(3):98‐101.
Andrade C. Mean difference, standardized mean difference (SMD), and their use in meta‐analysis: as simple as it gets. J Clin Psychiatry. 2020;81(5):20f13681. doi:10.4088/JCP.20f13681
Righini M, Goehring C, Bounameaux H, Perrier A. Effects of age on the performance of common diagnostic tests for pulmonary embolism. Am J Med. 2000;109(5):357‐361. doi:10.1016/s0002-9343(00)00493-9
Tita‐Nwa F, Bos A, Adjei A, Ershler WB, Longo DL, Ferrucci L. Correlates of D‐dimer in older persons. Aging Clin Exp Res. 2010;22(1):20‐23. doi:10.1007/BF03324810
Righini M, Van Es J, Den Exter PL, et al. Age‐adjusted D‐dimer cutoff levels to rule out pulmonary embolism: the ADJUST‐PE study. JAMA. 2014;311(11):1117‐1124. doi:10.1001/jama.2014.2135
Schouten HJ, Geersing GJ, Koek HL, et al. Diagnostic accuracy of conventional or age adjusted D‐dimer cut‐off values in older patients with suspected venous thromboembolism: systematic review and meta‐analysis. BMJ. 2013;346:f2492. doi:10.1136/bmj.f2492
Holmqvist ME, Neovius M, Eriksson J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. 2012;308(13):1350‐1356. doi:10.1001/2012.jama.11741
Choi HK, Rho YH, Zhu Y, Cea‐Soriano L, Aviña‐Zubieta JA, Zhang Y. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population‐based outpatient cohort study. Ann Rheum Dis. 2013;72(7):1182‐1187. doi:10.1136/annrheumdis-2012-201669
Li L, Lu N, Avina‐Galindo AM, et al. The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population‐based study. Rheumatology. 2021;60(1):188‐195. doi:10.1093/rheumatology/keaa262
Chung WS, Peng CL, Lin CL, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73(10):1774‐1780. doi:10.1136/annrheumdis-2013-203380
Conforti A, Berardicurti O, Pavlych V, Di Cola I, Cipriani P, Ruscitti P. Incidence of venous thromboembolism in rheumatoid arthritis, results from a “real‐life” cohort and an appraisal of available literature. Medicine. 2021;100(33):e26953. doi:10.1097/MD.0000000000026953
Pieper CF, Rao KMK, Currie MS, Harris TB, Cohen HJ. Age, functional status, and racial differences in plasma D‐dimer levels in community‐dwelling elderly persons. J Gerontol A Biol Sci Med Sci. 2000;55(11):M649‐M657. doi:10.1093/gerona/55.11.m649
Khaleghi M, Saleem U, McBane RD, Mosley Jr. TH, Kullo IJ. African‐American ethnicity is associated with higher plasma levels of D‐dimer in adults with hypertension. J Thromb Haemostasis. 2009;7(1):34‐40. doi:10.1111/j.1538-7836.2008.03215.x
Raffield LM, Zakai NA, Duan Q, et al. D‐dimer in African Americans: whole genome sequence analysis and relationship to cardiovascular disease risk in the Jackson Heart Study. Arterioscler Thromb Vasc Biol 2017;37(11):2220‐2227. doi:10.1161/ATVBAHA.117.310073